NetScientific (LSE:NSCI) FCF Margin % : -214.16% (As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is NetScientific FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. NetScientific's Free Cash Flow for the six months ended in Jun. 2023 was £-1.65 Mil. NetScientific's Revenue for the six months ended in Jun. 2023 was £0.77 Mil. Therefore, NetScientific's FCF Margin % for the quarter that ended in Jun. 2023 was -214.16%.

As of today, NetScientific's current FCF Yield % is -24.21%.

The historical rank and industry rank for NetScientific's FCF Margin % or its related term are showing as below:

LSE:NSCI' s FCF Margin % Range Over the Past 10 Years
Min: -52057.14 Med: -1644.83 Max: -264.14
Current: -264.14

During the past 13 years, the highest FCF Margin % of NetScientific was -264.14%. The lowest was -52057.14%. And the median was -1644.83%.

LSE:NSCI's FCF Margin % is ranked worse than
57.83% of 1034 companies
in the Biotechnology industry
Industry Median: -148.935 vs LSE:NSCI: -264.14

NetScientific FCF Margin % Historical Data

The historical data trend for NetScientific's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetScientific FCF Margin % Chart

NetScientific Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-3,425.71

-561.77

-730.96

-319.51

-314.74

NetScientific Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
FCF Margin %	Get a 7-Day Free Trial															-288.70	-337.43	-295.65	-326.92	-214.16

Competitive Comparison of NetScientific's FCF Margin %

For the Biotechnology subindustry, NetScientific's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NetScientific's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NetScientific's FCF Margin % distribution charts can be found below:

* The bar in red indicates where NetScientific's FCF Margin % falls into.

NetScientific FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

NetScientific's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-3.16	/	1.004
	=	-314.74 %

NetScientific's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-1.649	/	0.77
	=	-214.16 %

NetScientific FCF Margin % Related Terms

Thank you for viewing the detailed overview of NetScientific's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

NetScientific (LSE:NSCI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NetScientific PLC (LSE:NSCI) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 Saint Andrew Street, Holborn Circus, London, GBR, EC4A 3AG

Website

https://www.netscientific.net

NetScientific PLC is a transatlantic healthcare technology company. The group is focused on sourcing, funding and commercializing technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people. Its portfolio consists of WANDA Health, an analytics company that uses machine learning to derive a personalized risk score for Congestive Heart Failure patients, Glucosense a provider of a non-invasive glucose monitoring wearable device, Vortex Biosciences which is engaged in circulating tumor cell identification, selection and analysis for disease monitoring and personalized therapeutic prescribing, and Glycotest which provides non-invasive blood tests for liver cancers and fibrosis-cirrhosis.

NetScientific (LSE:NSCI) Headlines

No Headlines